302 related articles for article (PubMed ID: 29254220)
1. Expression of PD-1/PD-L1 and PD-L2 in peripheral T-cells from non-small cell lung cancer patients.
Arrieta O; Montes-Servín E; Hernandez-Martinez JM; Cardona AF; Casas-Ruiz E; Crispín JC; Motola D; Flores-Estrada D; Barrera L
Oncotarget; 2017 Nov; 8(60):101994-102005. PubMed ID: 29254220
[TBL] [Abstract][Full Text] [Related]
2. PD-L1 on peripheral blood T lymphocytes is prognostic in patients with non-small cell lung cancer (NSCLC) treated with EGFR inhibitors.
Meniawy TM; Lake RA; McDonnell AM; Millward MJ; Nowak AK
Lung Cancer; 2016 Mar; 93():9-16. PubMed ID: 26898608
[TBL] [Abstract][Full Text] [Related]
3. Clinicopathological analysis of PD-L1 and PD-L2 expression in pulmonary squamous cell carcinoma: Comparison with tumor-infiltrating T cells and the status of oncogenic drivers.
Kim MY; Koh J; Kim S; Go H; Jeon YK; Chung DH
Lung Cancer; 2015 Apr; 88(1):24-33. PubMed ID: 25662388
[TBL] [Abstract][Full Text] [Related]
4. Programmed death-1 ligand 1 and 2 are highly expressed in pleomorphic carcinomas of the lung: Comparison of sarcomatous and carcinomatous areas.
Kim S; Kim MY; Koh J; Go H; Lee DS; Jeon YK; Chung DH
Eur J Cancer; 2015 Nov; 51(17):2698-707. PubMed ID: 26329973
[TBL] [Abstract][Full Text] [Related]
5. Sarcomatoid lung carcinomas show high levels of programmed death ligand-1 (PD-L1) and strong immune-cell infiltration by TCD3 cells and macrophages.
Vieira T; Antoine M; Hamard C; Fallet V; Duruisseaux M; Rabbe N; Rodenas A; Cadranel J; Wislez M
Lung Cancer; 2016 Aug; 98():51-58. PubMed ID: 27393506
[TBL] [Abstract][Full Text] [Related]
6. Predictive relevance of PD-L1 expression combined with CD8+ TIL density in stage III non-small cell lung cancer patients receiving concurrent chemoradiotherapy.
Tokito T; Azuma K; Kawahara A; Ishii H; Yamada K; Matsuo N; Kinoshita T; Mizukami N; Ono H; Kage M; Hoshino T
Eur J Cancer; 2016 Mar; 55():7-14. PubMed ID: 26771872
[TBL] [Abstract][Full Text] [Related]
7. Changes in T lymphocyte subsets predict the efficacy of atezolizumab in advanced non-small cell lung cancer: a retrospective study.
Wang Y; Zhu J; Zhou N; Wang Y; Zhang X
J Thorac Dis; 2023 Oct; 15(10):5669-5679. PubMed ID: 37969284
[TBL] [Abstract][Full Text] [Related]
8. Loss of survival advantage for deficient mismatch repair in patients with advanced colorectal cancer may be caused by changes in prognostic value of CD8+T cell.
Wang B; Li F; Guo L; Lu S; Ma J; Ma Y; Meng Y; Wang J; Zhou X; Fu W
World J Surg Oncol; 2020 Aug; 18(1):196. PubMed ID: 32767974
[TBL] [Abstract][Full Text] [Related]
9. [Increased expressions of programmed death 1 (PD-1) and its ligands in peripheral CD3(+) T cells and CD19(+) B cells in patients with hepatocellular carcinoma].
Liu W; Chai L; Liang J; Lu Z; Yang S
Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2016 Sep; 32(9):1243-7. PubMed ID: 27609582
[TBL] [Abstract][Full Text] [Related]
10. Expression of PD-1 and Its Ligands, PD-L1 and PD-L2, in Smokers and Never Smokers with KRAS-Mutant Lung Cancer.
Calles A; Liao X; Sholl LM; Rodig SJ; Freeman GJ; Butaney M; Lydon C; Dahlberg SE; Hodi FS; Oxnard GR; Jackman DM; Jänne PA
J Thorac Oncol; 2015 Dec; 10(12):1726-35. PubMed ID: 26473645
[TBL] [Abstract][Full Text] [Related]
11. [Expression of PD-1/PD-L1 in peripheral blood mononuclear cells in lung cancer patients and its biological significance].
Xu P; Chen H; Chen YJ; Chen YB; Gu GH; Wu MY; Wu MJ; Wang XF; Zhang XG
Zhonghua Zhong Liu Za Zhi; 2013 Dec; 35(12):910-3. PubMed ID: 24506960
[TBL] [Abstract][Full Text] [Related]
12. Predictive relevance of PD-L1 expression with pre-existing TILs in gastric cancer.
Ju X; Shen R; Huang P; Zhai J; Qian X; Wang Q; Chen M
Oncotarget; 2017 Nov; 8(59):99372-99381. PubMed ID: 29245908
[TBL] [Abstract][Full Text] [Related]
13. Augmented expression of programmed death-1 in both neoplastic and non-neoplastic CD4+ T-cells in adult T-cell leukemia/lymphoma.
Shimauchi T; Kabashima K; Nakashima D; Sugita K; Yamada Y; Hino R; Tokura Y
Int J Cancer; 2007 Dec; 121(12):2585-90. PubMed ID: 17721918
[TBL] [Abstract][Full Text] [Related]
14. Programmed death-1
Singh A; Mohan A; Dey AB; Mitra DK
Clin Exp Immunol; 2017 Feb; 187(2):269-283. PubMed ID: 27665733
[TBL] [Abstract][Full Text] [Related]
15. The Impact of Biologic Treatment on PD-1/PD-L1 Pathway Disturbances in Psoriasis.
Adamczyk M; Bartosińska J; Raczkiewicz D; Michalak-Stoma A; Krasowska D
J Clin Med; 2023 Jun; 12(13):. PubMed ID: 37445214
[TBL] [Abstract][Full Text] [Related]
16. Increased expression of PD-L1 and PD-L2 in dermal fibroblasts from alopecia areata mice.
Li Y; Kilani RT; Pakyari M; Leung G; Nabai L; Ghahary A
J Cell Physiol; 2018 Mar; 233(3):2590-2601. PubMed ID: 28777458
[TBL] [Abstract][Full Text] [Related]
17. PD-L1, PD-L2 and PD-1 expression in metastatic melanoma: Correlation with tumor-infiltrating immune cells and clinical outcome.
Obeid JM; Erdag G; Smolkin ME; Deacon DH; Patterson JW; Chen L; Bullock TN; Slingluff CL
Oncoimmunology; 2016; 5(11):e1235107. PubMed ID: 27999753
[TBL] [Abstract][Full Text] [Related]
18. PD-L1 Expression Confers Better Prognosis in Locally Advanced Oral Squamous Cell Carcinoma.
Kogashiwa Y; Yasuda M; Sakurai H; Nakahira M; Sano Y; Gonda K; Ikeda T; Inoue H; Kuba K; Oba S; Ishikawa J; Enoki Y; Matsumura S; Minami K; Ebihara Y; Sugasawa M
Anticancer Res; 2017 Mar; 37(3):1417-1424. PubMed ID: 28314313
[TBL] [Abstract][Full Text] [Related]
19. Deep Sequencing of T-Cell Receptors for Monitoring Peripheral CD8
Sheng J; Wang H; Liu X; Deng Y; Yu Y; Xu P; Shou J; Pan H; Li H; Zhou X; Han W; Sun T; Pan H; Fang Y
Front Mol Biosci; 2021; 8():679130. PubMed ID: 34307450
[No Abstract] [Full Text] [Related]
20. Programmed death 1, ligand 1 and 2 correlated genes and their association with mutation, immune infiltration and clinical outcomes of hepatocellular carcinoma.
Sheng QJ; Tian WY; Dou XG; Zhang C; Li YW; Han C; Fan YX; Lai PP; Ding Y
World J Gastrointest Oncol; 2020 Nov; 12(11):1255-1271. PubMed ID: 33250959
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
